Nearly a century after insulin was discovered, an international team of researchers including University of Utah Health scientists report that they have developed the world’s smallest, fully functional version of the hormone, one that combines the potency of human insulin with the fast-acting potential of venom insulin produced by predatory cone snails. The finding, based on animal studies, could jumpstart the development of insulin treatments capable of improving the lives of those with diabetes.
“We now have the capability to create a hybrid version of insulin that works in humans and that also appears to have many of the positive attributes of cone snail insulin,” says Danny Hung-Chieh Chou, a U of U Health assistant professor of biochemistry and one of the study’s corresponding authors. “That’s an important step forward in our quest to make diabetes treatment safer and more effective.”
The study appears in Nature Structural and Molecular Biology.
As cone snails slither across coral reefs, they are constantly on the prowl for prey. Some of these fish-hunting species, such as Conus geographus, release plumes of toxic venom that contain a unique form of insulin into the surrounding water. The insulin causes fish blood glucose levels to plummet, temporarily paralyzing them. As the fish flounders, the snail emerges from its shell to swallow the subdued victim whole.
In earlier research, Chou and colleagues discovered that this venomous insulin had many biochemical traits in common with human insulin. Plus, it appears to work faster than the swiftest-acting human insulin currently available.
Faster-acting insulin would diminish the risk of hyperglycemia and other serious complications of diabetes, says Helena Safavi, a study co-author and an assistant professor of biomedical sciences at the University of Copenhagen in Denmark. It also could improve the performance of insulin pumps or artificial pancreas devices, which automatically release insulin into the body as needed. “We want to help people with diabetes to more tightly and rapidly control their blood sugar,” she says.
In pursuit of their goal, the researchers found that insulin derived from cone snail venom lacks a “hinge” component that causes human insulin to aggregate or clump together so it can be stored in the pancreas. These aggregates must break up into individual molecules before they can begin to work on blood sugar, a process that can take up to an hour. Since cone snail insulin doesn’t aggregate, it is in essence primed and ready to work on the body’s biochemical machinery almost immediately.
Intrigued, the researchers began to investigate ways to transform the insulin that cone snails use as a weapon into a different form: one that people who have Type 1 diabetes could use to rapidly restore equilibrium in their bodies.
“We had the idea of making human insulin more snail-like,” says Safavi, who is also an adjunct professor of biochemistry at U of U Health. “So, we sought to basically take some of the advantageous properties from the snail and graft them onto the human compound.”
The researchers thought this was possible because cone snail insulin essentially has the same basic structure or “backbone” as human insulin. However, they faced a dilemma: The snail’s insulin is far less potent than human insulin. In fact, the researchers suspect that humans would require 20 to 30 times more of the cone snail insulin to lower their blood sugar levels.
In this new study, Chou and colleagues sought to overcome these problems. First, they used structural biology and medicinal chemistry techniques to isolate four amino acids that help the snail insulin bind to the insulin receptor. Then, they created a truncated version of a human insulin molecule without the region responsible for clumping.
The team integrated modified versions of these amino acids into the human molecule in hopes of creating a hybrid that does not clump and binds the human insulin receptor with high potency.
In tests with laboratory rats, this hybrid insulin molecule, which the scientists call “mini-insulin,” interacted with insulin receptors in ways that cone snail insulin doesn’t. These new interactions bound mini-insulin to insulin receptors in the rat’s body just as strongly as normal human insulin would. As a result, mini-insulin had the same potency as human insulin but acted faster.
“Mini-insulin has tremendous potential,” Chou says. “With just a few strategic substitutions, we have generated a potent, fast-acting molecular structure that is the smallest, fully active insulin to date. Because it is so small, it should be easy to synthesize, making it a prime candidate for the development of a new generation of insulin therapeutics.”
In addition to Chou and Safavi, other U of U Health researchers involved in this study titled, “A structurally minimized yet fully active insulin based on cone-snail venom insulin principles, were X. Xiong, M. M. Disotuar, G. Ghabash, R. Agrawal, X. Wang, X. He, S. J. Fisher, J. Gajewiak and B. Olivera. The study was funded by the National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK) and the Australian National Health and Medical Research Council.
University of Utah Health provides leading-edge and compassionate medicine for a referral area that encompasses 10% of the U.S., including Idaho, Wyoming, Montana and much of Nevada. A hub for health sciences research and education in the region, U of U Health touts a $356 million research enterprise and trains the majority of Utah’s physicians and more than 1,250 health care providers each year at its Schools of Medicine and Dentistry and Colleges of Nursing, Pharmacy and Health. With more than 20,000 employees, the system includes 12 community clinics and four hospitals. For 10 straight years, U of U Health has ranked among the top 10 U.S. academic medical centers in the rigorous Vizient Quality and Accountability Study, including reaching No. 1 in 2010 and 2016.
Doug Dollemorescience writer, University of Utah Health
Office: 801-587-2596 email@example.com